Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease (Smell&Crohn)

This study will improve our understanding of the mechanisms underlying anorexia in persons with Crohn's disease flare-ups. The practical spin-off from this research is potentially very important for the management of nutritional disorders associated with the disease by guiding diets towards foods that correspond to patients' preferences and/or to modified tastes. In addition, the results could lead to the identification of sensory markers that herald an inflammatory flare-up of the disease.

Study Overview

• Status: Completed
• Conditions: Crohn's Disease; Olfactogustatory Perception
• Intervention / Treatment: Other: triangular test; Biological: blood sampling; Other: Questionnaires

• Study Type: Observational
• Enrollment (Actual): 62

Contacts and Locations

Study Locations

• France
  • Dijon, France, 21079
    • Centre Hospitalier Universitaire

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

understanding of the mechanisms underlying anorexia in persons with Crohn's disease flare-ups

Description

For patients :

Inclusion Criteria:

• Age between 18 and 60 years,
• Diagnosis of Crohn's disease according to clinical, endoscopic, histological, radiological and biochemical criteria as defined by the European Consensus Conference,
• Men or women who have provided consent and willing to cooperate.

Exclusion Criteria:

• Chronic inflammatory intestinal disease (CIID) other than Crohn's disease: haemorrhagic rectocolitis, undetermined colitis, microscopic colitis.
• Intercurrent disease (diabetes and metabolic disease, liver cirrhosis, progressive cancer, acute or chronic infection, Human Immunodeficiency Virus HIV),
• Organ failure (respiratory, heart, or renal failure, neurological disorders),
• Intolerance to gluten,
• Treatments (other than those used for Crohn's disease) able to interfere with food intake,
• Aversion to foods consumed or smelled,
• Poor understanding of cognitive tasks required.
• Crohn's disease complicated by an abscess or infectious complication
• Acute Crohn's disease defined by a CDAI score > 150

For Controls:

Inclusion Criteria:

• Adult person
• Without follow-up for a chronic pathology
• Having given its consent

Exclusion Criteria:

• Protected adult
• Person not affiliated to a social security system
• Pregnant or breastfeeding woman
• Active smoker
• No one who does not speak French
• Taking treatment that interferes with taste or acts on the central nervous system

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Crohn and anti-TNF treatment; Tests at 3 or 4 weeks after the beginning of anti-TNF treatment	Other: triangular test; metabolic state, impedance measurement, potential flavours evoked by sucrose,; Biological: blood sampling; sampling of 2 mL; Other: Questionnaires; Stunkard, PrefQuest
Crohn and without anti-TNF treatment; tests performed according to patient availability	Other: triangular test; metabolic state, impedance measurement, potential flavours evoked by sucrose,; Biological: blood sampling; sampling of 2 mL; Other: Questionnaires; Stunkard, PrefQuest
Control; tests performed according to patient availability	Other: triangular test; metabolic state, impedance measurement, potential flavours evoked by sucrose,; Biological: blood sampling; sampling of 2 mL; Other: Questionnaires; Stunkard, PrefQuest

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Modification of sweet taste	the measurement of detection thresholds consists in presenting to the participants in order of increasing concentrations, series of forced-choice triangular tests	through the study completion up to 10 years

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): October 7, 2013
• Primary Completion (Actual): May 3, 2021
• Study Completion (Actual): May 3, 2021

Study Registration Dates

• First Submitted: July 28, 2016
• First Submitted That Met QC Criteria: August 4, 2016
• First Posted (Estimated): August 9, 2016

Study Record Updates

• Last Update Posted (Estimated): February 22, 2024
• Last Update Submitted That Met QC Criteria: February 21, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Inflammatory Bowel Diseases; Inflammation; Crohn Disease
• Other Study ID Numbers: BRONDEL Ass INRA 2011

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No